NCT07603856招募中2 期
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 39
- 试验地点
- 1
研究概览
简要总结
Current clinical trials testing the combination of immunotherapy with radiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Disease-Related Criteria
- •Patients must have histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) with progression on prior immunotherapy
- •The patient's disease is eligible for SOC treatment with immunotherapy or chemotherapy.
- •Patients must have measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥10 mm (or ≥15 mm short axis for lymph nodes) by CT or MRI
- •Patients must have at least one lesion that meets criteria for hypofractionated ablative RT treatment:
- •Tumor volume 0.25 cc to 65 cc (approximately ≤5 cm maximal dimension)
- •Located in sites amenable to ablative RT (see radiotherapy section for specific anatomic criteria)
- •Note: Tumors >65 cc may be partially treated to 65 cc volume
- •Prior/Concurrent Therapy Criteria
- •Patients must have received exactly ONE prior line of anti-PD-1 or anti-PD-L1 therapy for non-small cell lung cancer. This therapy may have been given as:
- •Monotherapy
- •In combination with chemotherapy
- •In combination with another immunotherapy such as CTLA-4 inhibition
- •In combination with a targeted therapy, such as adagrasib
- •Special Cases for Neoadjuvant/Adjuvant Immunotherapy:
- •If patient received neoadjuvant, adjuvant, or consolidation anti-PD-1/PD-L1 therapy for Stage I-III disease and progressed ≤365 days from initiation (Cycle 1 Day 1), this counts as the single allowed therapy for advanced disease
- •If patient progressed >365 days from neoadjuvant/adjuvant therapy initiation, this does NOT count as therapy for advanced disease, and patient must have received subsequent anti-PD-1/PD-L1 therapy for Stage IV or recurrent disease
- •Patients with the following sensitizing mutations are ineligible, given known poor response to immunotherapy: EGFR, ALK, ROS1, RET, NTRK, HER
- •Patients with the following sensitizing mutations must have previously received at least one of the appropriate targeted therapies, in addition to prior immunotherapy: BRAF, KRAS, MET. Prior targeted therapy for participants with targetable alterations is allowed if all other eligibility criteria is also met.
- •Clinical/Laboratory Criteria
- •Age ≥18 years
- •ECOG Performance Status 0-2 (see Appendix A)
- •Participants must be able to safely receive the investigational drug combination and the investigator's choice of standard of care regimens described in Section 5.1 (Agent Administration), per the current FDA-approved package inserts, treating investigator's discretion, and institutional guidelines.
- •Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
- •Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Because radiation and chemotherapy are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Both men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of immunotherapy, radiation, and/or chemotherapy administration.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Patients with history of (non-infectious) pneumonitis requiring corticosteroids.
- •Patients with evidence of interstitial lung disease.
- •Patients with uncontrolled intercurrent illness.
- •Pregnant women are excluded from this study. Radiation is considered Class X and chemotherapy such as docetaxel are considered Class D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with radiation, immunotherapy, and chemotherapy breastfeeding should be discontinued if the mother is participating in the study.
- •Radiation-Specific Exclusions
- •Patients who have received prior radiation to any of the planned treatment sites (>10% dose overlap)
- •Patients with lesions in locations not amenable to safe ablative RT delivery, including:
- •Esophagus or stomach directly involved by tumor (unless dose constraints can be met)
- •Small bowel or colon directly involved by tumor (unless dose constraints can be met)
- •Spinal cord lesions with <3 mm clearance between epidural disease and spinal cord
研究组 & 干预措施
Standard Chemotherapy (Investigator's Choice")
Active Comparator
Participants will receive standard chemotherapy of investigator's choice.
干预措施: Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments) (Drug)
Radiotherapy (RT) + Immunotherapy
Experimental
Participants will receive standard immunotherapy of investigator's choice in combination with radiation treatment.
干预措施: Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) (Drug)
Radiotherapy (RT) + Immunotherapy
Experimental
Participants will receive standard immunotherapy of investigator's choice in combination with radiation treatment.
干预措施: Ablative Hypofractionated Radiotherapy (Radiation)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver MetastasesNCT07258147Sichuan University30
招募中
2 期
Immunotherapy With Adaptive Pulse Radiotherapy in Solid TumorsCancerNCT07381231Samsung Medical Center35
招募中
1 期
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRCNCT07281716Dan Feng24
尚未招募
2 期
Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II StudyNCT07467590Daping Hospital and the Research Institute of Surgery of the Third Military Medical University33
尚未招募
2 期
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell LymphomaNCT07634289Olivia Newton-John Cancer Research Institute40